IL6 and adult-onset Still disease: Previously, IL-1, IL-6 and TNF-α antagonists have been used as biologic therapies in patients with AOSD refractory to corticosteroids or conventional disease-modifying antirheumatic drugs (c-DMARDs) in clinical practice, but results from controlled clinical trials were missing [26].